Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates

Yonsei University Health System (YUHS)

Status: Completed

Conditions: Ductal Carcinoma in Situ

Treatments: Procedure: Mastectomy with sentinel lymph node biopsy

Study type: Observational

Funder types: Other

Identifiers

NCT05961280

3-2023-0026

Details and patient eligibility

About

This study aimed to assess the prevalence of upgrade to invasive breast cancer and axillary lymph node metastasis in patients who were diagnosed with DCIS on biopsy and subsequently underwent mastectomy with axillary surgery to establish the need for SLNB. Furthermore, we explored the clinicopathologic features related to the upgrade to invasive breast cancer and axillary lymph node metastasis.

Enrollment: 385 patients

Sex: Female

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Women diagnosed with DCIS in preoperative biopsy samples obtained by core needle biopsy, vacuum-assisted breast biopsy, or excisional biopsy
2. Women underwent curative surgery for DCIS

Exclusion criteria

1. Patients who received breast-conserving surgery
2. Patients who had concurrent contralateral invasive breast cancer
3. Patients who were in case of ipsilateral breast tumor recurrence
4. Patients whose invasiveness was uncertain in the biopsy samples

Trial design

385 participants in 1 patient group

DCIS Mastectomy

Description:

Patients who undergo mastectomy with sentinel lymph node biopsy for DCIS at biopsy

Treatment:

Procedure: Mastectomy with sentinel lymph node biopsy